The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: A prospective longitudinal observational cohort study

Arthritis Research and Therapy

Volumn 14, Issue 2, 2012, Pages

  Arends, Suzanne ^a,b   Spoorenberg, Anneke ^a,b   Houtman, Pieternella M ^b   Leijsma, Martha K ^a   Bos, Reinhard ^b   Kallenberg, Cees G M ^a   Groen, Henk ^a   Brouwer, Elisabeth ^a   van der Veer, Eveline ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; ETANERCEPT; INFLIXIMAB; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLERGIC REACTION; ANKYLOSING SPONDYLITIS; ARTICLE; BONE DENSITY; BONE TURNOVER; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; DEMYELINATING DISEASE; DIARRHEA; DISEASE ACTIVITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FOLLOW UP; HIP; HUMAN; INFECTION; LABORATORY TEST; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PREDICTIVE VALUE; QUALITY OF LIFE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; UVEITIS; BLOOD; BONE REMODELING; COHORT ANALYSIS; DRUG ANTAGONISM; DRUG EFFECT; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BONE REMODELING; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861303162     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3823     Document Type: Article

References (34)

1. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?. Arthritis Rheum 2005, 52:1000-1008. 10.1002/art.20990, 15818678.
2. Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, Braun J. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007, 66:910-915. 10.1136/ard.2006.066415, 1955120, 17329306.
3. Geusens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 2007, 19:335-339. 10.1097/BOR.0b013e328133f5b3, 17551362.
4. Vosse D, Landewe R, van der Heijde D, van der Linden S, van Staa TP, Geusens P. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 2009, 68:1839-1842. 10.1136/ard.2008.100503, 19066179.
5. Arends S, Spoorenberg A, Bruyn GA, Houtman PM, Leijsma MK, Kallenberg CG, Brouwer E, van der Veer E. The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int 2011, 22:1431-1439. 10.1007/s00198-010-1338-7, 3073049, 20603707.
6. Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N, van der Heijde D. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008, 59:1270-1278. 10.1002/art.24001, 18759257.
7. Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola EM, Paolozzi L, Salvarani C, Sanmarti R, Sibilia J, Sieper J, van den Bosch F, van der Heijde D, van der Linden S, Wajdula J. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009, 36:1256-1264. 10.3899/jrheum.081033, 19411393.
8. van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009, 68:922-929. 10.1136/ard.2007.087270, 2674550, 18701556.
9. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005, 64:1462-1466. 10.1136/ard.2004.033472, 1755223, 15778240.
10. van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008, 58:1324-1331. 10.1002/art.23471, 18438853.
11. van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, Ballal S, Gibson E, Wong R. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009, 11:R127. 10.1186/ar2794, 2745811, 19703304.
12. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010, 69:2002-2008. 10.1136/ard.2009.124446, 20511613.
13. Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken) 2010, 62:1362-1369.
14. Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Jansen TL, Kallenberg CG, Spoorenberg A. Baseline predictors of response and discontinuation of TNF-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011, 13:R94. 10.1186/ar3369, 3218909, 21689401.
15. van der Heijde D, Lie E, Kvien TK, Sieper J, van den Bosch F, Listing J, Braun J, Landewe R. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:1811-1818. 10.1136/ard.2008.100826, 19060001.
16. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:18-24.
17. Xu M, Lin Z, Deng X, Li L, Wie Y, Liao Z, Li Q, Wie Q, Hu Z, Zhang Y, Lin Q, Huang J, Li T, Pan Y, Wu Y, Jin O, Yu B, Gu J. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-{alpha} inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China. Rheumatology (Oxford) 2011, 50:1466-1472.
18. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011, 22:391-420. 10.1007/s00198-010-1501-1, 21184054.
19. Woo JH, Lee HJ, Sung IH, Kim TH. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007, 34:1753-1759.
20. Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther 2008, 10:R125. 10.1186/ar2537, 2592815, 18945353.
21. Pedersen SJ, Sorensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Jurik AG, Moller J, Hasselquist M, Mikkelsen D, Skjodt T, Lambert R, Hansen A, Ostergaard M. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis 2011, 70:1375-1381. 10.1136/ard.2010.138883, 21551511.
22. Maksymowych WP, Rahman P, Shojania K, Olszynski WP, Thomson GT, Ballal S, Wong RL, Inman RD. Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 2008, 35:2030-2037.
23. Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, Braun J. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:175-182. 10.1136/ard.2007.084426, 2605572, 18495735.
24. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368. 10.1002/art.1780270401, 6231933.
25. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, Landewe R, Maksymowych W, van der Heijde D. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009, 68(Suppl 2):ii1-44. 10.1136/ard.2008.104018, 19433414.
26. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, Rudwaleit M, Braun J. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011, 70:905-908. 10.1136/ard.2011.151563, 21540200.
27. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994, 4:368-381. 10.1007/BF01622200, 7696835.
28. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988, 240:1285-1293. 10.1126/science.3287615, 3287615.
29. Meirelles ES, Borelli A, Camargo OP. Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol 1999, 18:364-68. 10.1007/s100670050120, 10524549.
30. Baek HJ, Kang SW, Lee YJ, Shin KC, Lee EB, Yoo CD, eSong YW. Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int 2005, 26:30-34. 10.1007/s00296-004-0516-3, 15480679.
31. van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008, 58:1324-1331. 10.1002/art.23471, 18438853.
32. van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Williamson P, Xu W, Baker D, Goldstein N, Braun J. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008, 58:3063-3070. 10.1002/art.23901, 18821688.
33. van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H, Ballal S, Gbison E, Wong R. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009, 11:R127. 10.1186/ar2794, 2745811, 19703304.
34. Briot K, Gossec L, Kolta S, Dougados M, Roux C. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiver anti-tumor necrosis factor-α treatment. J Rheumatol 2008, 35:855-861.